{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:52:31Z","timestamp":1793757151826,"version":"4.6.1"},"reference-count":97,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>HIV continues to spread among vulnerable heterosexual (HET), Men-having-Sex with Men (MSM) and intravenous drug user (IDU) populations, influenced by a complex array of biological, behavioral and societal factors. Phylogenetics analyses of large sequence datasets from national drug resistance testing programs reveal the evolutionary interrelationships of viral strains implicated in the dynamic spread of HIV in different regional settings. Viral phylogenetics can be combined with demographic and behavioral information to gain insights on epidemiological processes shaping transmission networks at the population-level. Drug resistance testing programs also reveal emergent mutational pathways leading to resistance to the 23 antiretroviral drugs used in HIV-1 management in low-, middle- and high-income settings. This article describes how genotypic and phylogenetic information from Quebec and elsewhere provide critical information on HIV transmission and resistance, Cumulative findings can be used to optimize public health strategies to tackle the challenges of HIV in \u201creal-world\u201d settings.<\/jats:p>","DOI":"10.3390\/v10010010","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T11:24:33Z","timestamp":1514460273000},"page":"10","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in \u201cReal-World\u201d Settings"],"prefix":"10.3390","volume":"10","author":[{"given":"Bluma","family":"Brenner","sequence":"first","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra-Ilinca","family":"Ibanescu","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Hardy","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Microbiologie et d\u2019Immunologie et Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, QC H2X 0A9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Roger","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Microbiologie et d\u2019Immunologie et Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, QC H2X 0A9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(10)70186-9","article-title":"Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease","volume":"11","author":"Tebit","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkg079","article-title":"Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance","volume":"51","author":"Spira","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/01.aids.0000432449.30239.fe","article-title":"The increase in global HIV epidemics in MSM","volume":"27","author":"Beyrer","year":"2013","journal-title":"AIDS"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/aid.2016.0061","article-title":"Short Communication: Phylogenetic Evidence of HIV-1 Transmission Between Adult and Adolescent Men Who Have Sex with Men","volume":"33","author":"Wolf","year":"2017","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.meegid.2016.05.041","article-title":"The global spread of HIV-1 subtype B epidemic","volume":"46","author":"Magiorkinis","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.meegid.2016.06.033","article-title":"Molecular epidemiology of HIV-1 infection in Europe: An overview","volume":"46","author":"Beloukas","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0140-6736(10)60936-1","article-title":"Association of highly active antiretroviral therapy coverage, population viral load and yearly new HIV diagnoses in British Columbia, Canada: A population-based study","volume":"376","author":"Montaner","year":"2010","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0140-6736(13)62230-8","article-title":"Transformation of HIV from pandemic to low-endemic levels: A public health approach to combination prevention","volume":"384","author":"Jones","year":"2014","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM200003303421303","article-title":"Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group","volume":"342","author":"Quinn","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15867","DOI":"10.1073\/pnas.1418496111","article-title":"Impact of early-stage HIV transmission on treatment as prevention","volume":"111","author":"Powers","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/QAI.0000000000001285","article-title":"Europe Africa Research Network for Evaluation of Second-line Therapy Trial, T.; HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa","volume":"75","author":"Kityo","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1097\/QAD.0000000000001233","article-title":"In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa","volume":"30","author":"Vidal","year":"2016","journal-title":"AIDS"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1097\/QAD.0000000000001234","article-title":"We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance","volume":"30","author":"Brenner","year":"2016","journal-title":"AIDS"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","article-title":"Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance","volume":"239","author":"Brenner","year":"2017","journal-title":"Virus Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMp1710608","article-title":"HIV Drug Resistance\u2014An Emerging Threat to Epidemic Control","volume":"377","author":"Beyrer","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMra1004180","article-title":"Development of antiretroviral drug resistance","volume":"365","author":"Wainberg","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kantor, R., Katzenstein, D.A., Efron, B., Carvalho, A.P., Wynhoven, B., Cane, P., Clarke, J., Sirivichayakul, S., Soares, M.A., and Snoeck, J. (2005). Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020112"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1128\/JVI.00495-16","article-title":"HIV-1 Protease, Reverse Transcriptase and Integrase Variation","volume":"90","author":"Rhee","year":"2016","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2017.03.024","article-title":"Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration","volume":"18","author":"Rhee","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1086\/600073","article-title":"Predictive value of HIV-1 genotypic resistance test interpretation algorithms","volume":"200","author":"Rhee","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/COH.0b013e32833a6c32","article-title":"Highly active antiretroviral treatment as prevention of HIV transmission: Review of scientific evidence and update","volume":"5","author":"Granich","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11904-014-0202-3","article-title":"The HIV epidemic in Eastern Europe and Central Asia","volume":"11","author":"DeHovitz","year":"2014","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/COH.0000000000000035","article-title":"Drug use as a driver of HIV risks: Re-emerging and emerging issues","volume":"9","author":"Shaw","year":"2014","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/2325957413488196","article-title":"French HIV experts on early antiretroviral treatment for prevention: Uncertainty and heterogeneity","volume":"13","author":"Lebouche","year":"2014","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"key":"ref_26","first-page":"35","article-title":"CROI 2017: HIV Epidemic Trends and Advances in Prevention","volume":"25","author":"Liu","year":"2017","journal-title":"Top. Antivir. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/QAD.0000000000001383","article-title":"Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec","volume":"31","author":"Brenner","year":"2017","journal-title":"AIDS"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S2352-3018(16)00046-1","article-title":"Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: An implementation case study","volume":"3","author":"Poon","year":"2016","journal-title":"Lancet HIV"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/QAD.0b013e32835cffd9","article-title":"Phylogenetic inferences on HIV-1 transmission: Implications for the design of prevention and treatment interventions","volume":"27","author":"Brenner","year":"2013","journal-title":"AIDS"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/512088","article-title":"High rates of forward transmission events after acute\/early HIV-1 infection","volume":"195","author":"Brenner","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bezemer, D., Cori, A., Ratmann, O., van Sighem, A., Hermanides, H.S., Dutilh, B.E., Gras, L., Rodrigues Faria, N., van den Hengel, R., and Duits, A.J. (2015). Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic Analysis. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001898"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/aid.2013.0171","article-title":"HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya","volume":"30","author":"Bezemer","year":"2014","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/molbev\/msw217","article-title":"Phylogenetic Tools for Generalized HIV-1 Epidemics: Findings from the PANGEA-HIV Methods Comparison","volume":"34","author":"Ratmann","year":"2017","journal-title":"Mol. Biol. Evol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"320ra2","DOI":"10.1126\/scitranslmed.aad1863","article-title":"Sources of HIV infection among men having sex with men and implications for prevention","volume":"8","author":"Ratmann","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/651951","article-title":"Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland","volume":"201","author":"Kouyos","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/cid\/civ732","article-title":"HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study","volume":"62","author":"Marzel","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"27580","DOI":"10.1038\/srep27580","article-title":"Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland","volume":"6","author":"Shilaih","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Villandre, L., Stephens, D.A., Labbe, A., Gunthard, H.F., Kouyos, R., Stadler, T., and Swiss HIV Cohort Study (2016). Assessment of Overlap of Phylogenetic Transmission Clusters and Communities in Simple Sexual Contact Networks: Applications to HIV-1. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148459"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/infdis\/jir468","article-title":"Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec","volume":"204","author":"Brenner","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1097\/QAD.0b013e3283121c90","article-title":"Transmission networks of drug resistance acquired in primary\/early stage HIV infection","volume":"22","author":"Brenner","year":"2008","journal-title":"AIDS"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1097\/QAI.0b013e3182986f96","article-title":"Future of phylogeny in HIV prevention","volume":"63","author":"Brenner","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/QAD.0b013e328333ddee","article-title":"Transmission networks of HIV-1 among men having sex with men in the Netherlands","volume":"24","author":"Bezemer","year":"2010","journal-title":"AIDS"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/infdis\/jir550","article-title":"Transmission network parameters estimated from HIV sequences for a nationwide epidemic","volume":"204","author":"Lycett","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Wainberg, M.A., Mesplede, T., and Raffi, F. (2013). What if HIV were unable to develop resistance against a new therapeutic agent?. BMC Med., 11.","DOI":"10.1186\/1741-7015-11-249"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1001\/jama.279.24.1977","article-title":"Public health implications of antiretroviral therapy and HIV drug resistance","volume":"279","author":"Wainberg","year":"1998","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1071\/SH16056","article-title":"Enhanced use of phylogenetic data to inform public health approaches to HIV among men who have sex with men","volume":"14","author":"German","year":"2016","journal-title":"Sex. Health"},{"key":"ref_47","unstructured":"Brenner BG, I.R., Roger, M., Oliveira, M., Hardy, I., and Wainberg, M.A. (2017, January 21\u201322). Phylogenetic, Epidemiological and Virological Insights on the Rise of Large Cluster Outbreaks Fueling the HIV-1 Epidemic among Men Having Sex with Men within Quebec. Proceedings of the 12th International Workshop on HIV Transmission-Principles of Intervention;, Paris, France."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"vew010","DOI":"10.1093\/ve\/vew010","article-title":"HIV-1 transmission between MSM and heterosexuals and increasing proportions of circulating recombinant forms in the Nordic Countries","volume":"2","author":"Esbjornsson","year":"2016","journal-title":"Virus Evol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/QAD.0000000000001470","article-title":"Defining HIV-1 transmission clusters based on sequence data","volume":"31","author":"Hassan","year":"2017","journal-title":"AIDS"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"19962","DOI":"10.2807\/ese.16.36.19962-en","article-title":"HIV-1 outbreak among injecting drug users in Greece, 2011: A preliminary report","volume":"16","author":"Paraskevis","year":"2011","journal-title":"Euro Surveill."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1099\/vir.0.000107","article-title":"Analysis of the history and spread of HIV-1 in Uganda using phylodynamics","volume":"96","author":"Yebra","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/QAD.0000000000000383","article-title":"Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions","volume":"28","author":"Hue","year":"2014","journal-title":"AIDS"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/infdis\/jiv758","article-title":"Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters","volume":"213","author":"Lycett","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/QAD.0000000000000298","article-title":"Estimating per-act HIV transmission risk: A systematic review","volume":"28","author":"Patel","year":"2014","journal-title":"AIDS"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/1570162033352110","article-title":"Measuring the infectiousness of persons with HIV-1: Opportunities for preventing sexual HIV-1 transmission","volume":"1","author":"Baeten","year":"2003","journal-title":"Curr. HIV Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1128\/JVI.02660-07","article-title":"Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing","volume":"82","author":"Bailes","year":"2008","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMra1011874","article-title":"Acute HIV-1 Infection","volume":"364","author":"Cohen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1086\/529206","article-title":"HIV-1 variation before seroconversion in men who have sex with men: Analysis of acute\/early HIV infection in the multicenter AIDS cohort study","volume":"197","author":"Gottlieb","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Vrbik, I., Stephens, D.A., Roger, M., and Brenner, B.G. (2015). The Gap Procedure: For the identification of phylogenetic clusters in HIV-1 sequence data. BMC Bioinform., 16.","DOI":"10.1186\/s12859-015-0791-x"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lessells, R.J., Stott, K.E., Manasa, J., Naidu, K.K., Skingsley, A., Rossouw, T., and de Oliveira, T. (2014). Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: Early experiences, achievements and challenges. BMC Health Serv. Res., 14.","DOI":"10.1186\/1472-6963-14-116"},{"key":"ref_62","first-page":"221","article-title":"Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: Needs, opportunities and challenges","volume":"15","author":"Lessells","year":"2013","journal-title":"AIDS Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/jac\/dkx118","article-title":"HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton\/small clusters","volume":"72","author":"Brenner","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nrmicro3471","article-title":"Bottlenecks in HIV-1 transmission: Insights from the study of founder viruses","volume":"13","author":"Joseph","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E590","DOI":"10.1073\/pnas.1620144114","article-title":"Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness","volume":"114","author":"Iyer","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","first-page":"10","article-title":"CROI 2016: Hot Spots in HIV Infection and Advances in HIV Prevention","volume":"24","author":"Buchbinder","year":"2016","journal-title":"Top. Antivir. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/0956462415602420","article-title":"Ability of a rapid HIV testing site to attract and test vulnerable populations: A cross-sectional study on Actuel sur Rue","volume":"27","author":"Engler","year":"2016","journal-title":"Int. J. STD AIDS"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/jac\/dkw071","article-title":"Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors","volume":"71","author":"Brenner","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12981-016-0130-y","article-title":"Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: A preliminary bioinformatics study","volume":"14","author":"Palanisamy","year":"2017","journal-title":"AIDS Res. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/jmv.22047","article-title":"Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors","volume":"83","author":"Brenner","year":"2011","journal-title":"J. Med. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Rhee, S.Y., Blanco, J.L., Jordan, M.R., Taylor, J., Lemey, P., Varghese, V., Hamers, R.L., Bertagnolio, S., Rinke de Wit, T.F., and Aghokeng, A.F. (2015). Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: An individual-patient- and sequence-level meta-analysis. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001845"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1126\/science.271.5253.1282","article-title":"Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase","volume":"271","author":"Wainberg","year":"1996","journal-title":"Science"},{"key":"ref_73","first-page":"224","article-title":"Might the M184V substitution in HIV-1 RT confer clinical benefit?","volume":"4","author":"Petrella","year":"2002","journal-title":"AIDS Rev."},{"key":"ref_74","first-page":"31","article-title":"Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients","volume":"27","author":"Turner","year":"2004","journal-title":"New Microbiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","article-title":"A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","volume":"17","author":"Brenner","year":"2003","journal-title":"AIDS"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/hiv.09.40","article-title":"The K65R mutation in HIV-1 reverse transcriptase: Genetic barriers, resistance profile and clinical implications","volume":"3","author":"Brenner","year":"2009","journal-title":"HIV Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","article-title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture","volume":"20","author":"Brenner","year":"2006","journal-title":"AIDS"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/QAD.0b013e32832d40ad","article-title":"The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection","volume":"23","author":"Yerly","year":"2009","journal-title":"AIDS"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Charest, H., Doualla-Bell, F., Cantin, R., Murphy, D.G., Lemieux, L., Brenner, B., Hardy, I., Moisi, D., Lo, E., and Baril, J.G. (2014). A Significant Reduction in the Frequency of HIV-1 Drug Resistance in Quebec from 2001 to 2011 Is Associated with a Decrease in the Monitored Viral Load. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109420"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 Week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief Report: Dolutegravir Plus Abacavir\/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 Week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/IDR.S58706","article-title":"The role of dolutegravir in the management of HIV infection","volume":"8","author":"Miller","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3018(16)30016-9","article-title":"Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): A randomised, controlled, double-blind, phase 3 study","volume":"3","author":"Squires","year":"2016","journal-title":"Lancet HIV"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Kaplan, R., and Wood, R. (2017). Resistance to first-line ART and a role for dolutegravir. Lancet HIV.","DOI":"10.1016\/S2352-3018(17)30207-2"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Phillips, A.N., Cambiano, V., Nakagawa, F., Revill, P., Jordan, M.R., Hallett, T.B., Doherty, M., De Luca, A., Lundgren, J.D., and Mhangara, M. (2017). Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: A modelling study. Lancet HIV.","DOI":"10.1016\/S2352-3018(17)30190-X"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/COH.0000000000000389","article-title":"The ADVANCE study: A groundbreaking trial to evaluate a candidate universal antiretroviral regimen","volume":"12","author":"Venter","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAD.0000000000000519","article-title":"Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials","volume":"29","author":"Raffi","year":"2015","journal-title":"AIDS"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1097\/QAD.0000000000000813","article-title":"Hit me with your best shot: Dolutegravir\u2014A space in the next WHO guidelines?","volume":"29","author":"Cohn","year":"2015","journal-title":"AIDS"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"20824","DOI":"10.7448\/IAS.18.1.20824","article-title":"Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy","volume":"18","author":"Wainberg","year":"2015","journal-title":"J. Int. AIDS Soc."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1097\/QAD.0000000000000888","article-title":"Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1","volume":"29","author":"Pinnetti","year":"2015","journal-title":"AIDS"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/jac\/dku058","article-title":"Has the time come to abandon efavirenz for first-line antiretroviral therapy?","volume":"69","author":"Raffi","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/cid\/civ963","article-title":"Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe","volume":"62","author":"Hofstra","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","article-title":"HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study","volume":"11","author":"Hamers","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1128\/AAC.01720-09","article-title":"Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors","volume":"54","author":"Armenia","year":"2010","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/1\/10\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:55:50Z","timestamp":1760208950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/1\/10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,28]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"alternative-id":["v10010010"],"URL":"https:\/\/doi.org\/10.3390\/v10010010","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,28]]}}}